---
title: "Prime Medicine, Inc. (PRME.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/PRME.US.md"
symbol: "PRME.US"
name: "Prime Medicine, Inc."
industry: "Biotechnology"
---

# Prime Medicine, Inc. (PRME.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [rimemedicine.com](https://rimemedicine.com) |

## Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically m...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-02T04:30:14.000Z

**Overall: D (0.60)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 226 / 405 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 647.13% |  |
| Net Profit YoY | 9.99% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 5.15 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 833.96M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 5.98M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -112.34% | E |
| Profit Margin | -3301.64% | E |
| Gross Margin | -3491.02% | E |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 647.13% | A |
| Net Profit YoY | 9.99% | C |
| Total Assets YoY | 15.69% | A |
| Net Assets YoY | -14.61% | E |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -3.03% | D |
| OCF YoY | 647.13% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.02 | E |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 57.97% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Prime Medicine, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-112.34%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-3301.64%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-3491.02%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "647.13%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "9.99%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "15.69%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-14.61%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-3.03%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "647.13%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "57.97%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | MiMedx (US.MDXG) | A | B | A | B | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.23 | 353/606 | - | - | - |
| PB | 5.15 | 309/606 | 7.65 | 4.07 | 1.63 |
| PS (TTM) | 139.53 | 266/606 | 135.30 | 104.41 | 72.33 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 6 | 50% |
| Overweight | 1 | 8% |
| Hold | 4 | 33% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.63 |
| Highest Target | 9.00 |
| Lowest Target | 4.25 |

## References

- [Company Overview](https://longbridge.com/en/quote/PRME.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/PRME.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/PRME.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.